Eclosion
Chemin Des Aulx 14, Plan-les-Ouates, Geneva, 1228, Switzerland
Overview
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up can reasonably attract risk capital. Eclosion helps you to cross the bridge to convert your innovation into a realistic venture and to enter into its growth phase.
- Total investments
- 3
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Genkyotex
Participated · Series D · Jan 2015
Genkyotex develops selective NOX1&4 inhibitors, with lead candidate GKT137831 in clinical development for diabetic nephropathy. The company plans to use the financing to complete a Phase 2 trial of GKT137831, advance a second drug into Phase 1, and broaden its NOX inhibitor pipeline. Its NOX inhibitors have shown potential in fibrotic and inflammatory disorders of the kidney, liver, lung and skin. Management expects top-line data from the Phase 2a study of GKT137831 in mid-2015. The company said the proceeds will allow it to continue independent development through Phase 2 results and prepare for the next phase of trials. Genkyotex is developing first‑in‑class small‑molecule therapeutics that selectively inhibit the NOX family of enzymes. Its lead compound, the NOX1/4 inhibitor GKT137831, showed safety and tolerability in single‑dose Phase Ia studies and is in a multi‑dose Phase Ib study expected to finish later this quarter. The company plans to advance GKT137831 into Phase II for diabetic nephropathy and to progress additional pipeline molecules targeting other diseases. Proceeds from the recent financing will fund the Phase II program and broader clinical development. Genkyotex has expanded its management team with Eric Meldrum as Chief Scientific Officer and Alexandre Grassin as finance director. Founded in 2006 and linked to Geneva and Archamps, France, the company uses a unique screening platform to identify selective NOX inhibitors. Genkyotex, based in Geneva, completed a financing round in May that totaled CHF 18 million. The article does not detail the use of proceeds, investors, or the instrument beyond calling it a financing round. The fundraising is presented as part of a broader signal that venture activity in biotech startups was healthy in the first half of 2011. Ernst & Young’s newly published data for the period are cited to support that view. Jürg Zürcher, Partner and Biotechnology Leader EMEIA at Ernst & Young, is quoted saying investments were essentially stable compared with 2010. No operating metrics, past rounds, founding year, or additional financial details are provided in the article.
Team
No current team members are available.